A 38-year-old woman from Bangalore presents with a 6-week history of persistent cough. A tuberculin skin test (TST) is performed and shows 12 mm induration (patient is immunocompetent, non-BCG vaccinated). The prevalence of active TB in her district is 250 per 100,000 population. What is the most appropriate next step in management?

Explanation

## Clinical Context This question tests the application of test sensitivity, specificity, and NPV in a real-world TB screening scenario — a cornerstone of NEET PG biostatistics and Indian public health. ## Understanding TST Performance **Key Point:** TST (Mantoux test) has high sensitivity (~80%) but modest specificity (~70%) in immunocompetent individuals. A positive TST indicates TB infection (latent or active), NOT necessarily active disease. ## Calculating Negative Predictive Value (NPV) NPV is the probability of NOT having disease given a negative test. With TST sensitivity ~80%: $$NPV = \frac{\text{Specificity} \times (1 - \text{Pretest Probability})}{(\text{Specificity} \times (1 - \text{Pretest Probability})) + (1 - \text{Sensitivity}) \times \text{Pretest Probability}}$$ In this case: - Pretest probability (prevalence) = 250/100,000 = 0.0025 (very low in general population) - A negative TST would have very high NPV (>99%), effectively ruling out active TB - A positive TST does NOT rule in active TB — further testing is mandatory ## Likelihood Ratios | Test Result | Likelihood Ratio | Clinical Interpretation | |---|---|---| | TST positive (12 mm) | LR+ ≈ 2.7 | Weak to moderate evidence for TB infection | | TST negative | LR− ≈ 0.2 | Moderate evidence against TB infection | **High-Yield:** A positive TST with LR+ of ~2.7 modestly increases the probability of TB from baseline, but does NOT confirm active disease. Clinical and radiological correlation is essential. ## Why Chest X-ray and Sputum Smear? 1. **Differentiate latent from active TB:** TST cannot distinguish between latent TB infection (LTBI) and active TB disease 2. **Identify active disease:** CXR may show infiltrates, cavitation, or other TB-suggestive findings 3. **Confirm infectivity:** Sputum smear microscopy detects acid-fast bacilli (AFB), confirming active pulmonary TB 4. **Guide treatment:** Only active TB requires anti-tuberculous therapy; LTBI is managed differently **Clinical Pearl:** In a symptomatic patient (6-week cough) with a positive TST, the pretest probability of active TB is higher than in asymptomatic screening. Imaging and bacteriology are the gold standard to confirm active disease. ## Management Algorithm ```mermaid flowchart TD A[Symptomatic patient + positive TST]:::outcome --> B[Calculate pretest probability of active TB]:::action B --> C{Clinical suspicion for active TB?}:::decision C -->|Yes, symptoms present| D[CXR + sputum smear microscopy]:::action C -->|No, asymptomatic| E[Evaluate for LTBI vs active TB]:::action D --> F{AFB positive or CXR suggestive?}:::decision F -->|Yes| G[Confirm TB, start ATT]:::action F -->|No| H[Rule out TB, investigate other causes]:::action E --> I[Consider LTBI treatment if risk factors present]:::action ``` **Mnemonic:** **TST-CXR-AFB** — The diagnostic triad for TB confirmation: Tuberculin Skin Test (screening), Chest X-Ray (imaging), Acid-Fast Bacilli (bacteriology). ## Why NOT Start ATT Immediately? **Warning:** Starting anti-tuberculous therapy based on TST alone (without confirming active disease) risks: - Unnecessary drug exposure and toxicity in patients with LTBI - Masking of alternative diagnoses (fungal infection, malignancy, other pneumonia) - Potential drug interactions and adverse effects - Violation of TB diagnostic guidelines (WHO, RNTCP, NTEP)